Post-stroke cognitive impairment is associated with poorer return-to-work outcomes in working-aged stroke survivors: A systematic review.

Clin RehabilFeb 10, 2026 (epub)
Clinical ResearchNeurology

Libby J Cunningham, Tadhg Stapleton, Killian Walsh et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review examined how post-stroke cognitive impairment relates to return-to-work outcomes among working-aged stroke survivors and assessed cognitive measures used in the literature. It included 39 studies: 33 observational, five qualitative and one randomised trial. Across cohorts, reported cognitive impairment prevalence ranged from 17.5% at 28 days to 89% at 7 years, while return-to-work rates ranged from 7.5% to 100%. Despite substantial variation in assessment methods and timing, cognition was the factor most commonly associated with return-to-work outcomes, and impairment was linked to poorer outcomes even after milder stroke.

Key findings

  • Cognitive impairment prevalence ranged from 17.5% at 28 days to 89% at 7 years across study cohorts.
  • Return-to-work rates ranged from 7.5% to 100%, with no clear trends by time after stroke or stroke subtype.
  • Cognition was the most commonly associated factor influencing return-to-work outcomes, followed by stroke severity, mood and functional status.
  • Concentration, memory and processing speed impairments were most frequently reported.

Why it matters

Cognitive difficulties may affect employment after stroke even when the stroke is mild, yet their effects can be less visible than physical disability. The review also highlights inconsistent assessment practices and limited awareness among employers and clinicians. Recognising this evidence can help frame return-to-work assessment as involving cognitive as well as physical and functional outcomes.

What to keep in mind

Substantial heterogeneity in cognitive assessments, assessment timing and study designs required narrative synthesis, limiting direct comparison across studies. The evidence base included only one randomised trial.

Source

Published in Clin Rehabil. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.